Is Bruker Corporation profitable in 2026?

Bruker guided FY2026 non-GAAP EPS of $2.10-$2.15 on revenue of $3.57-$3.60B, reaffirmed May 6, 2026. FY2025 revenue was $3.44B, up 2.1% reported but down about 4% organically, showing profitability persists even as organic growth stays negative.

Is Bruker Corporation laying off employees?

Bruker's headcount fell to about 11,085 employees at end of 2025, down 311 (2.7%) from 11,396 at end of 2024, per its 10-K reported July 17, 2026. It is the company's first workforce contraction after several years of double-digit growth.

Could AI replace Bruker Corporation's instruments business?

No. Bruker's core is capital-intensive hardware, superconducting magnets, ultra-high-field NMR, and mass spectrometers, backed by over 5,000 patents and 15 manufacturing facilities per a June 2026 market report. AI is layered on as analytics software like AtoMx and Spatial Discovery, not a hardware replacement.

Who is Bruker Corporation's biggest competitor?

Thermo Fisher Scientific is Bruker's most cited rival. Its Orbitrap Astral platform is regaining share from Bruker's timsTOF technology in high-end proteomics mass spectrometry, per a third-party competitive analysis published June 18, 2026.

Who owns Bruker Corporation?

Bruker is an independent public company trading on Nasdaq as BRKR, with market capitalization of roughly $9.47 billion as of July 24, 2026. It has no controlling parent; Dr. Frank H. Laukien serves as Chairman, President, and CEO.

Is Bruker Corporation's revenue growing?

Reported revenue grew but organic sales shrank: FY2025 revenue was $3.44B (up 2.1% yoy) yet down about 4% organically due to NIH funding cuts and tariffs, per SEC filing dated February 12, 2026. Q1-26 organic revenue fell a further 4.4%.

Biotech tools companies · United States

Bruker Corporation

bruker.com ↗

Maker of NMR, mass spec, and microscopy instruments for life science and materials labs.

Defensible for now

Assessed 24 July 2026 · Evidence as of 24 July 2026

Real protection, with named pressure against it.

On the recordSince 24 July 2026 · Checkable from August 2026 · Every call on the record Checkpoint: Q2 2026 earnings, testing whether book-to-bill above 1.0x finally turns organic revenue positive

The call

Bruker's magnet and NMR business still locks in customers through service revenue, even as Thermo Fisher's newer mass spec line pulls proteomics deals away.

Bruker builds machines that scientists use to study molecules, especially nuclear magnetic resonance devices and mass spectrometers that are hard to replace once installed. The company is losing sales right now because research funding is tight and tariffs are rising, and Thermo Fisher is winning back customers in advanced protein analysis with a new competing machine called Orbitrap Astral. The biggest question is whether Bruker can grow again as demand recovers, or whether Thermo Fisher keeps stealing share in mass spectrometry and spreads to other product lines.

Why

AI pressure: None apparent. No AI-native rival is reported taking Bruker's instrument sales; AI tools mostly speed up analysis of data its machines generate. Could AI do the core job? Unlikely.

Bigger players: Thermo Fisher Scientific (Orbitrap Astral platform). Thermo Fisher's Orbitrap Astral is winning back high-end proteomics mass-spec deals that used to go to Bruker's timsTOF line. Could a giant copy it? No, they are blocked.

What protects it. 38% of revenue now comes from recurring service and consumables tied to thousands of installed NMR and mass-spec systems, plus a large patent base on magnet tech.

What would change this call

Bruker's organic revenue growth turns positive in Q2 or Q3 2026 earnings. Shows whether book-to-bill recovery is converting into actual demand, not just backlog.
Thermo Fisher's Orbitrap Astral share gains extend beyond high-end proteomics into other mass spec categories. Would show Bruker's losses spreading past one niche into broader mass spectrometry business.
US NIH FY2027 budget finalizes with the proposed 12% cut and July 2026 tariffs take effect as planned. Would confirm external funding and trade headwinds are pressuring Bruker's academic/government customer base.

Key numbers

FY2025 revenue $3.44B, down about 4% organically (2026-02-12)
Q1 2026 revenue $823.4M, down 4.4% organically (2026-05-06)
Recurring aftermarket revenue hit 38% of BSI sales (2026-02-12)

Named risks

US NIH FY2027 budget proposal includes a further 12% funding cut, threatening academic demand. Severity: high
New broad US tariffs of 10-12.5% announced July 24, 2026 could add cost pressure similar to 2025's ~$40M hit. Severity: medium
Thermo Fisher's Orbitrap Astral share gains could spread beyond proteomics into other mass spec categories. Severity: medium
Organic revenue has declined roughly 4% for two consecutive years despite recovering order bookings. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Thermo Fisher Scientific	losing to	Orbitrap Astral regaining high-end proteomics share from Bruker timsTOF, per analysis published 2026-06-18
Agilent Technologies	contesting	Named alongside Thermo Fisher as top incumbent in mass spec and clinical-lab markets, 2026-01-23 report
Waters Corporation	contesting	Repeatedly cited as principal rival across chromatography and mass spectrometry in 2026 market reports
Danaher (SCIEX)	contesting	Named as core competitor across analytical instrumentation in 2026 industry coverage
Shimadzu Corporation	contesting	Listed among principal mass spectrometry and chromatography rivals in 2026 market reports

Questions people ask

Is Bruker Corporation profitable in 2026?: Bruker guided FY2026 non-GAAP EPS of $2.10-$2.15 on revenue of $3.57-$3.60B, reaffirmed May 6, 2026. FY2025 revenue was $3.44B, up 2.1% reported but down about 4% organically, showing profitability persists even as organic growth stays negative.
Is Bruker Corporation laying off employees?: Bruker's headcount fell to about 11,085 employees at end of 2025, down 311 (2.7%) from 11,396 at end of 2024, per its 10-K reported July 17, 2026. It is the company's first workforce contraction after several years of double-digit growth.
Could AI replace Bruker Corporation's instruments business?: No. Bruker's core is capital-intensive hardware, superconducting magnets, ultra-high-field NMR, and mass spectrometers, backed by over 5,000 patents and 15 manufacturing facilities per a June 2026 market report. AI is layered on as analytics software like AtoMx and Spatial Discovery, not a hardware replacement.
Who is Bruker Corporation's biggest competitor?: Thermo Fisher Scientific is Bruker's most cited rival. Its Orbitrap Astral platform is regaining share from Bruker's timsTOF technology in high-end proteomics mass spectrometry, per a third-party competitive analysis published June 18, 2026.
Who owns Bruker Corporation?: Bruker is an independent public company trading on Nasdaq as BRKR, with market capitalization of roughly $9.47 billion as of July 24, 2026. It has no controlling parent; Dr. Frank H. Laukien serves as Chairman, President, and CEO.
Is Bruker Corporation's revenue growing?: Reported revenue grew but organic sales shrank: FY2025 revenue was $3.44B (up 2.1% yoy) yet down about 4% organically due to NIH funding cuts and tariffs, per SEC filing dated February 12, 2026. Q1-26 organic revenue fell a further 4.4%.

Timeline

2026-07-24Bruker market cap reaches approximately $9.47B amid new US tariff announcement
2026-07-15Bruker acquires DISQVER metagenomic mNGS platform from Noscendo for infection detection
2026-05-06Q1-26 results: revenue $823.4M, up 2.7% yoy but down 4.4% organically, book-to-bill above 1.0x third straight quarter
2026-02-25Bruker launches CellScape XR clinical-translation spatial proteomics platform
2026-02-23Bruker unveils AGBT spatial biology advancements including AI-ready AtoMx platform
2026-02-12FY2025 and Q4-25 results: FY revenue $3.44B, Q4 revenue $977.2M flat yoy
2026-01-31Bruker completes acquisition of TOFWERK AG
2025-06-30Bruker acquires biocrates life sciences
2024-05-31Bruker acquires NanoString Technologies business
2023-12-31Bruker acquires PhenomeX for $108M

Revision history

24 July 2026

First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.

In the same band

DiaSorin S.p.A.Spectris plc Tecan Group